This study is designed to evaluate the safety and appropriate dose of the combination of
Temodar and Sutent as first-line therapy for patients with metastatic malignant melanoma
(Phase 1). Once the safety and appropriate dose is determined, additional patients will be
studied at that dose to determine if there is clinical benefit as determined by the primary
end-point of progression-free survival (PFS) at 6 months and additional secondary endpoints
(Phase II).